Home / BPC-157 / Side effects

BPC-157 side effects

Not FDA-approved BPC-157 has never been through a controlled human trial. This is what the FDA found when it reviewed the evidence in 2026.

Short answer: Nobody knows how common its side effects are. The FDA found only five tiny human studies (2 to about 26 people each) and says there is "insufficient clinical safety information to characterize the safety profile of BPC-157." Injected or nasal use may trigger an immune reaction, and products sold online can contain impurities.

What the evidence shows

Controlled human trialsNone. The FDA found no human studies of under-the-skin, oral, nasal or skin use
Largest human dataFive small studies (enema, joint, bladder and IV use), short and with limited safety monitoring
2025 IV pilot2 healthy adults given 10 mg then 20 mg IV; no side effects reported; no control group
FDA adverse event reportsInjection site reaction, shortness of breath, skin or gum darkening; cause not established
Immune reaction riskFDA: injected or nasal BPC-157 "may pose a significant risk for immunogenicity"; oral risk likely low
ImpuritiesFDA flags peptide-related impurities and difficulty characterizing the ingredient
Status (Nov 2026)Not FDA-approved. An advisory committee voted 8-6 to allow compounding (non-binding); HHS has a draft policy, not a final rule

Not medical advice. Contact your prescriber about side effects that are severe or do not go away, and get urgent care for severe stomach pain, signs of an allergic reaction or trouble breathing.

More on BPC-157: dosage and status ·units calculator

Side effects of: Tirzepatide · Semaglutide · Retatrutide

Questions

What are the side effects of BPC-157?
There is no reliable list, because there are no controlled human trials. Reports to the FDA include injection site reactions, shortness of breath and skin darkening, but those cannot prove BPC-157 caused them.
Is BPC-157 safe?
Unknown. The FDA says there is not enough clinical safety information to characterize it, and its staff recommended against adding it to the compounding list in 2026.
Is oral BPC-157 safer than injecting it?
The FDA judged the immune-reaction risk as likely low for oral use and potentially significant for injected or nasal use. That is about one risk, not overall safety.

Sources

  1. FDA briefing document: BPC-157, Pharmacy Compounding Advisory Committee, July 23-24, 2026
  2. FDA: Certain bulk drug substances for compounding that may present significant safety risks
  3. Lee & Burgess 2025: IV BPC-157 safety pilot in two adults (PubMed)
  4. PharmExec: FDA advisory committee votes to loosen restrictions on peptides (Jul 2026)
  5. Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)

Last checked 2026-11-16. How we pick and check sources: methodology.